Close
4

Quotient Sciences Quotient Sciences

X

Find Upadacitinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Looking for 1310726-60-3 / Upadacitinib API manufacturers, exporters & distributors?

Upadacitinib manufacturers, exporters & distributors 1

30

PharmaCompass offers a list of Upadacitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Upadacitinib manufacturer or Upadacitinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Upadacitinib manufacturer or Upadacitinib supplier.

PharmaCompass also assists you with knowing the Upadacitinib API Price utilized in the formulation of products. Upadacitinib API Price is not always fixed or binding as the Upadacitinib Price is obtained through a variety of data sources. The Upadacitinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Upadacitinib

Synonyms

1310726-60-3, Abt-494, Rinvoq, Upadacitinib anhydrous, 4ra0kn46e0, (3s,4r)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

Cas Number

1310726-60-3

Unique Ingredient Identifier (UNII)

4RA0KN46E0

About Upadacitinib

Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved Upadacitinib in August 2019 for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, it was additionally approved by the European Commission for the same indication in patients with inadequate response or intolerance to one or more DMARDs and can be used as monotherapy or in combination with methotrexate. Upadacitinib is marketed under the brand name RINVOQ for oral administration. It is currently being investigated in several clinical trials assessing its therapeutic effectiveness in other inflammatory diseases, such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.

Upadacitinib Tartrate Manufacturers

A Upadacitinib Tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Upadacitinib Tartrate, including repackagers and relabelers. The FDA regulates Upadacitinib Tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Upadacitinib Tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Upadacitinib Tartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Upadacitinib Tartrate Suppliers

A Upadacitinib Tartrate supplier is an individual or a company that provides Upadacitinib Tartrate active pharmaceutical ingredient (API) or Upadacitinib Tartrate finished formulations upon request. The Upadacitinib Tartrate suppliers may include Upadacitinib Tartrate API manufacturers, exporters, distributors and traders.

click here to find a list of Upadacitinib Tartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Upadacitinib Tartrate USDMF

A Upadacitinib Tartrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Upadacitinib Tartrate active pharmaceutical ingredient (API) in detail. Different forms of Upadacitinib Tartrate DMFs exist exist since differing nations have different regulations, such as Upadacitinib Tartrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Upadacitinib Tartrate DMF submitted to regulatory agencies in the US is known as a USDMF. Upadacitinib Tartrate USDMF includes data on Upadacitinib Tartrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Upadacitinib Tartrate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Upadacitinib Tartrate suppliers with USDMF on PharmaCompass.

Upadacitinib Tartrate KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Upadacitinib Tartrate Drug Master File in Korea (Upadacitinib Tartrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Upadacitinib Tartrate. The MFDS reviews the Upadacitinib Tartrate KDMF as part of the drug registration process and uses the information provided in the Upadacitinib Tartrate KDMF to evaluate the safety and efficacy of the drug.

After submitting a Upadacitinib Tartrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Upadacitinib Tartrate API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Upadacitinib Tartrate suppliers with KDMF on PharmaCompass.

Upadacitinib Tartrate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Upadacitinib Tartrate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Upadacitinib Tartrate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Upadacitinib Tartrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Upadacitinib Tartrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Upadacitinib Tartrate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Upadacitinib Tartrate suppliers with NDC on PharmaCompass.

Upadacitinib Tartrate GMP

Upadacitinib Tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Upadacitinib Tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Upadacitinib Tartrate GMP manufacturer or Upadacitinib Tartrate GMP API supplier for your needs.

Upadacitinib Tartrate CoA

A Upadacitinib Tartrate CoA (Certificate of Analysis) is a formal document that attests to Upadacitinib Tartrate's compliance with Upadacitinib Tartrate specifications and serves as a tool for batch-level quality control.

Upadacitinib Tartrate CoA mostly includes findings from lab analyses of a specific batch. For each Upadacitinib Tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Upadacitinib Tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Upadacitinib Tartrate EP), Upadacitinib Tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Upadacitinib Tartrate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY